CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.81: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.74%Below 5Y avg (0.93%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
41.7%Sustainable
Last Ex-Dividend
Jul 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.53BCNY377.69M · vs all stocks (USD)
Trailing P/E
53.33xRevenue (TTM)
832.86MCNY124.37M · vs all stocks (USD)
Profit Margin
5.39%Beta
0.3270xvs all stocks
52-Week Change
-20.06%vs all stocks
Market Capitalization
2.53BCNY377.69M · vs all stocks (USD)
Enterprise Value
2.15BCNY320.50M · vs all stocks (USD)
Trailing P/E
53.33xPrice to Sales (TTM)
2.91xPrice to Book (MRQ)
1.51xEnterprise to Revenue
2.58xEnterprise to EBITDA
15.74xGross Margin
28.13%Profit Margin
5.39%Operating Margin
7.83%Return on Assets (TTM)
1.62%Return on Equity (TTM)
3.32%Revenue (TTM)
832.86MCNY124.37M · vs all stocks (USD)
Revenue per Share (TTM)
4.50CNYUpdated Sep 22, 2026Quarterly Revenue Growth
1.20%Gross Profit (TTM)
206.36MCNY30.82M · vs all stocks (USD)
EBITDA (TTM)
71.66MCNY10.70M · vs all stocks (USD)
Net Income (TTM)
44.88MCNY6.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-54.30%Operating Cash Flow (TTM)
126.65MCNY18.91M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
25.76MCNY3.85M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.74%vs all stocks
5-Year Average Dividend Yield
0.93%vs all stocks
Payout Ratio
41.67%Minority Interest (Equity)
30.25MCNYFY2025 · Dec 31, 2025Revenue
844.54MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
623.66MCNYFY2025 · Dec 31, 2025Gross Profit
220.87MCNYFY2025 · Dec 31, 2025Operating Income
84.49MCNY12.62M · vs all stocks (USD)
Pre-tax Income
80.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
10.86MCNYFY2025 · Dec 31, 2025Net Income
69.26MCNYFY2025 · Dec 31, 2025EBIT
81.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
169.66MCNYFY2025 · Dec 31, 2025Research & Development
53.67MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
21.23MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
908.93KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
177.59MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
177.59MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
69.26MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-7.11MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
42.66MCNYFY2025 · Dec 31, 2025Free Cash Flow
-101.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
402.77MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
69.26MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.35MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.85MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-144.55MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.55BCNYFY2025 · Dec 31, 2025Sale of Investments
1.37BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-317.21MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
141.50MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-79.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.81MCNYFY2025 · Dec 31, 2025Other Financing Charges
264.38MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
319.07MCNYFY2025 · Dec 31, 2025Shares Outstanding
189.03MSharesUpdated Sep 22, 2026Float Shares
91.12MSharesUpdated Sep 22, 2026% Held by Insiders
51.12%vs all stocks
% Held by Institutions
3.23%vs all stocks
Total Cash (MRQ)
626.35MCNY93.53M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.34CNYUpdated Sep 22, 2026Total Debt (MRQ)
339.14MCNY50.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2091xCurrent Ratio (MRQ)
3.56xBook Value per Share (MRQ)
8.47CNYUpdated Sep 22, 2026Total Assets
2.20BCNY328.31M · vs all stocks (USD)
Total Current Assets
1.01BCNYFY2025 · Dec 31, 2025Total Liabilities
583.75MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.19BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
337.05MCNYFY2025 · Dec 31, 2025Total Current Liabilities
246.70MCNYFY2025 · Dec 31, 2025Cash
427.47MCNYFY2025 · Dec 31, 2025Cash Equivalents
30.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
457.67MCNYFY2025 · Dec 31, 2025Other Short-term Investments
182.06MCNYFY2025 · Dec 31, 2025Accounts Receivable
152.83MCNYFY2025 · Dec 31, 2025Inventory
189.74MCNYFY2025 · Dec 31, 2025Accounts Payable
182.18MCNYFY2025 · Dec 31, 2025Short-term Debt
6.32MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.14MCNYFY2025 · Dec 31, 2025Long-term Debt
317.75MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
8.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
189.03MCNYFY2025 · Dec 31, 2025Retained Earnings
444.88MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.61BCNY241.14M · vs all stocks (USD)
Treasury Stock
21.13MCNYFY2025 · Dec 31, 202552-Week Low
9.94CNYUpdated Sep 22, 202652-Week High
22.00CNYUpdated Sep 22, 202652-Week Change
-20.06%vs all stocks
Beta
0.3270xvs all stocks
50-Day MA
12.24CNYUpdated Sep 22, 2026200-Day MA
15.55CNYUpdated Sep 22, 2026Avg 10-Day Volume
4.36MSharesUpdated Sep 22, 2026Avg 30-Day Volume
10.05MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.2400CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.81: safe zoneNotable
Altman Z-Score: 3.81
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule